News
26 February 2021
DEFACTO selects VIVEbiotech to include it in its project
The marketing and communication consultancy DEFACTO has selected VIVEbiotech as a chameleon company that has known how to adapt to the COVID-19 crisis.
Read more26 February 2021
VIVEbiotech finalist of the National SME 2020 Award
VIVEbiotech has been one of the five finalists of the National SME 2020 Award.
Read more)
24 February 2021
VIVEbiotech is expanding its manufacturing capabilities with new facilities
VIVEbiotech expands facilities to increase innovation and manufacturing capabilities of specialist lentiviral vectors.
Read more10 February 2021
Renewal of the CIR Certification from the Government of France
VIVEbiotech obtains the renewal of the CIR Certification from the Ministry of Higher Education, Research and Innovation of the Government of France.
Read more)
10 February 2021
Authorization to manufacture investigational medicinal products
VIVEbiotech obtains authorization to manufacture investigational medicinal products.
Read more8 February 2021
In 2021 we continue to participate in congresses
Successful participation of VIVEbiotech in three international conferences in Q1 2021.
Read more)
21 January 2021
Webinar on Cell & Gene Therapy Insights
VIVEbiotech and Polyplus-transfection give a webinar on Cell & Gene Therapy Insights.
Read more)
8 January 2021
VIVEbiotech collaborates with Emendo Biotherapeutics
VIVEbiotech today announces a collaboration with Emendo Biotherapeutics.
Read more)
16 December 2020
VIVEbiotech winner of the 2020 Gipuzkoa SME Award
VIVEbiotech has been the winner of the 2020 Gipuzkoa SME Award which was awarded by the Spanish Chamber of Commerce and Banco Santander.
Read more)
11 December 2020
Igone Bravo participates in the Industria Eguna 2020 of ADEGI
Igone Bravo, a technician in the R&D Department of VIVEbiotech, participates in the Industria Eguna 2020 of ADEGI
Read moreDestacadas
)
)
)
)
){kind=spacer}
4 March 2024
Spanish researchers to design proteins using AI to make advanced therapies more efficient
)
)
14 February 2024
VIVEbiotech forecasts significant growth in lentiviral vectors and CAR-T therapies for 2024
)
)
9 February 2024
)